Clinical Treatment and Outcomes of Gastrointestinal Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 August 2026 | Viewed by 2

Special Issue Editor


E-Mail Website
Guest Editor
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Interests: pancreatic cancer; biliary tract cancer; disease modeling; cost effectiveness

Special Issue Information

Dear Colleagues,

The landscape of treatment for gastrointestinal oncology has evolved over the last decade to take advantage of novel therapeutics, evolving molecular targets, and changes in the delivery of care. We are seeking papers that highlight these changes and where GI cancer care is going next.

Molecular targets are expanding the potential therapeutic landscape for both luminal and extraluminal GI cancers. As Claudin 18.2, FGFR, and HER-2 become the standard of care, the next wave of potential targets is under investigation. Existing pathways such as Wnt, KRAS, and TGFb are being targeted in new ways, and novel approaches to epigenetic modifications (ARID1A, EZH2) are being developed. Although immunotherapy approaches have led to substantial gains for some GI malignancies, others have proved recalcitrant and we are now turning to dual therapy with cytotoxic therapy, joint IO therapy, and cellular therapy to attempt to broaden the reach of these paradigms.

From a care delivery standpoint, GI oncology has some very real constraints. The length and toxicity of some regimens, the logistical burden of continuous infusion 5FU that is the backbone of many cytotoxic regimens, and the challenges of daily chemoradiotherapy all burden our patients with high-intensity, high-cost, high-toxicity treatments. Novel approaches to care delivery, appropriate patient selection including pharmacogenetic information, and evaluation of functional, financial, and time toxicity are all necessary additions to practice.

In this Special Issue, we seek to explore the clinical landscape of gastrointestinal malignancy, including screening, diagnosis, and treatment of this diverse group of cancers. We have particular interest in rare tumor types (neuroendocrine tumors, GIST, biliary tract, ampullary, gallbladder, appendiceal). We are also interested in highlighting patient-focused research, from screening to financial toxicity.

Dr. Mary Linton Peters
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancer
  • ctDNA
  • chemotherapy
  • immunotherapy
  • financial toxicity
  • clinical trial participation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop